SpyGlass Pharma, Inc. 8-K

What Happened
SpyGlass Pharma, Inc. announced its quarterly financial results for the quarter ended March 31, 2026 by issuing a press release dated May 14, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8‑K (Item 2.02: Results of Operations and Financial Condition) filed with the SEC on May 14, 2026. The Form 8‑K was signed by Jean‑Frédéric Viret, Ph.D., Chief Financial Officer.

Key Details

• Form 8‑K filed May 14, 2026 reporting results for the quarter ended March 31, 2026 (Item 2.02).
• Press release dated May 14, 2026 furnished as Exhibit 99.1 to the Form 8‑K.
• Filing signed by CFO Jean‑Frédéric Viret, Ph.D.
• The 8‑K itself does not include financial line‑item figures — see Exhibit 99.1 (press release) for revenue, earnings, cash positions and other metrics.

Why It Matters
Quarterly results provide updated information on SpyGlass Pharma’s earnings, revenue and financial condition that can affect valuation and investor decisions. Retail investors should review the press release (Exhibit 99.1) and the company’s published financial statements for the specific numbers and context, and consult the full filing on SEC EDGAR or the company’s investor relations page for details.